Amylin
A pancreatic hormone co-secreted with insulin that slows gastric emptying and produces satiety.
Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic β-cells. It complements insulin's metabolic effects by slowing gastric emptying, suppressing post-meal glucagon, and producing central satiety via amylin receptors in the area postrema. Synthetic amylin analogues with improved stability are research targets for chronic weight management — pramlintide (Symlin) is an FDA-approved analogue requiring multiple daily injections, and cagrilintide is the long-acting once-weekly research compound currently in phase 3.
- ResearchCagrilintide 10 mg
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.
- BiomarkerFasting insulin 12
Fasting insulin of 12 µIU/mL is above the optimal threshold most metabolic research uses (~8). What it indicates, why doctors miss it, and the research literature on early insulin resistance.
- BiomarkerHbA1c 5.7%
HbA1c at 5.7% is the formal threshold the ADA uses to define prediabetes — meaning your average blood glucose has been elevated over the past 2–3 months. What the number means and the research literature on intervention.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue